Abbhi Capital

Clinical Research IO is a health technology company based in Boston, Massachusetts, specializing in e-source and site operation software for clinical research sites. The company's platform allows users to build and customize clinical source templates from a comprehensive library, facilitating the identification and correction of source data errors. Additionally, it manages patient compliance through scheduling features and automated text reminders, enhancing both patient recruitment and retention with dedicated modules. By providing a unified system for regulatory workflows, Clinical Research IO supports pharmaceutical companies, biotech firms, research sites, and academic institutions in streamlining their clinical research processes.

BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing adult stem cell therapies for neurodegenerative diseases. Their proprietary technology, NurOwn, utilizes a patient's own mesenchymal stem cells, which are engineered to produce neurotrophic factors that promote neuronal survival. The company is actively advancing NurOwn through clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. Currently, NurOwn is in a Phase III clinical trial for ALS and a Phase II trial for MS, with plans for preclinical studies targeting Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. BrainStorm has partnered with Catalent for the manufacturing of NurOwn, ensuring the production of this autologous cellular therapy. Founded in 2000 and headquartered in New York, BrainStorm Cell Therapeutics was previously known as Golden Hand Resources Inc. before rebranding in 2004.